Non-alcoholic fatty liver disease affects 20–40% of the population. Its active form, non-
alcoholic steatohepatitis (NASH), is characterised by hepatocyte injury, liver inflammation …

Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is likely to become the
most common cause of chronic liver disease in the next decade, worldwide. Though …

Nonalcoholic fatty liver disease remains a major cause of liver-related morbidity and
mortality worldwide. It is a complex disease associated with obesity, diabetes, and …

It is important to provide treatment to patients with nonalcoholic steatohepatitis (NASH)
because one third of patients with the metabolic syndrome die of liver disease. Basic …

Non‐alcoholic steatohepatitis (NASH) is the most common cause of liver disease in Western
populations, and its prevalence is increasing rapidly. It is part of a multisystem disease …

The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in
the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
in the West. Non-alcoholic steatohepatitis (NASH) is the progressive form of NAFLD and can …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

Introduction: Nonalcoholic steatohepatitis (NASH) is a disease of increasing prevalence with
morbidity and mortality closely related to cardiovascular disease, malignancies and …

There has been a rise in the prevalence of non-alcohol fatty liver disease (NAFLD) due to
the popularity of western diets and sedentary lifestyles. One quarter of NAFLD patients is …